(Q41035618)

25 September 2017

PD-L1 protein expression in breast cancer is rare, enriched in basal-like tumours and associated with infiltrating lymphocytes (English)

1 reference

25 September 2017

S Bowden

10

0 references

Janet A Dunn

object named as

J Dunn

8

0 references

Carlos Caldas

13

object named as

C Caldas

1 reference

25 September 2017

12

P D P Pharoah

1 reference

25 September 2017

H R Ali

1

1 reference

25 September 2017

S-E Glont

2

1 reference

25 September 2017

F M Blows

3

1 reference

25 September 2017

E Provenzano

4

1 reference

25 September 2017

S-J Dawson

5

1 reference

25 September 2017

B Liu

6

1 reference

25 September 2017

L Hiller

7

1 reference

25 September 2017

C J Poole

9

1 reference

25 September 2017

H M Earl

11

1 reference

25 September 2017

20 April 2015

1 reference

25 September 2017

1 reference

25 September 2017

26

1 reference

25 September 2017

7

1 reference

25 September 2017

1488-1493

1 reference

Improved Survival with Ipilimumab in Patients with Metastatic Melanoma

25 September 2017

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV192

Safety, activity, and immune correlates of anti-PD-1 antibody in cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV192

Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV192

MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV192

The novel costimulatory programmed death ligand 1/B7.1 pathway is functional in inhibiting alloimmune responses in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV192

Programmed death-1 ligand 1 interacts specifically with the B7-1 costimulatory molecule to inhibit T cell responses

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV192

B7-H1/CD80 interaction is required for the induction and maintenance of peripheral T-cell tolerance

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV192

Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV192

Association between CD8+ T-cell infiltration and breast cancer survival in 12,439 patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV192

Allelic association of the human homologue of the mouse modifier Ptprj with breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV192

Epirubicin and cyclophosphamide, methotrexate, and fluorouracil as adjuvant therapy for early breast cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV192

The shaping and functional consequences of the microRNA landscape in breast cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV192

Subtyping of breast cancer by immunohistochemistry to investigate a relationship between subtype and short and long term survival: a collaborative analysis of data for 10,159 cases from 12 studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV192

A tumor DNA complex aberration index is an independent predictor of survival in breast and ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV192

TP53 mutation spectrum in breast cancer is subtype specific and has distinct prognostic relevance

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV192

PD-L1 expression is characteristic of a subset of aggressive B-cell lymphomas and virus-associated malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV192

Expression of programmed death ligand 1 (PD-L1) is associated with poor prognosis in human breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV192

Unvalidated antibodies and misleading results

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV192

In situ tumor PD-L1 mRNA expression is associated with increased TILs and better outcome in breast carcinomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV192

Prognostic and predictive value of PDL1 expression in breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV192

Checkpoint blockade cancer immunotherapy targets tumour-specific mutant antigens

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV192

Genetic basis for clinical response to CTLA-4 blockade in melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV192

Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV192

Comprehensive molecular characterization of gastric adenocarcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV192

PD-1 blockade with nivolumab in relapsed or refractory Hodgkin's lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV192

PD-L1 expression is increased in a subset of basal type breast cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV192

21 January 2018

Identifiers

DOI

10.1093/ANNONC/MDV192

1 reference

25 September 2017

1 reference